Daewoong Pharmaceutical R&D Center

Daewoong Pharmaceutical is a leading South Korean pharmaceutical company focused on developing and commercializing innovative medicines across a broad range of therapeutic areas. The company is well-known for its global botulinum toxin brand, Nabota, and has recently launched significant in-house developed products such as Fexuprazan for gastric acid-related diseases and Enavogliflozin for diabetes. Daewoong operates a robust R&D network with centers in Korea, China, and the United States, emphasizing open collaboration and the development of first-in-class and best-in-class therapies. Their portfolio spans small molecules, biologics, and cell therapies, targeting high-unmet-need conditions like idiopathic pulmonary fibrosis and autoimmune disorders.